LRRK2 and Cognitive impairment: It has been demonstrated that some nonmotor symptoms in MDS‐UPDRS I, like cognitive impairment and autonomic dysfunction, can precede dopamine transporter deficit in nonmanifesting LRRK2 mutation carriers.15